Ryoncil: The First FDA-Approved MSC Therapy Explained

For years, people selling stem cells have waved around the phrase "FDA-approved" like it was a free pass.

Most of the time it wasn't. Lab registration is not product approval. A trial is not a license. And "stem cell therapy" is not one product. It is a pile of different cell types, different sources, different doses, and different regulatory paths.

Then, on December 18, 2024, the FDA did something it had never done before. It approved an allogeneic mesenchymal stromal cell (MSC) product as a drug.

The product is called Ryoncil. The generic name is remestemcel-L-rknd. It is made from bone marrow MSCs, and it is approved for one hard, specific condition in children: steroid-refractory acute graft-versus-host disease after a transplant (FDA, December 18, 2024).

That matters. It also does not mean every MSC product on the market is now FDA-approved. Including ours. Let's keep the story straight.

What Is Ryoncil?

Ryoncil is an off-the-shelf cell therapy. The cells come from the bone marrow of healthy adult donors. They are culture-expanded mesenchymal stromal cells, then given as an intravenous infusion.

The approved indication is narrow on purpose. Steroid-refractory acute graft-versus-host disease (SR-aGVHD) is a life-threatening complication that can hit after an allogeneic blood or marrow transplant. The donor's immune cells attack the patient's tissues. Steroids are first-line treatment. When steroids fail, options get thin fast, especially in young children.

Ryoncil is approved for pediatric patients 2 months of age and older with that condition. The recommended dose on the FDA label is 2 × 10⁶ MSCs per kilogram of body weight, given twice a week for four consecutive weeks, for a total of eight infusions, at least three days apart.

That is a drug. It went through a Biologics License Application. The FDA reviewed manufacturing, safety, and efficacy the same way it reviews other cellular biologics. That is a different path from products marketed under HCT/P 361 rules.

What Did the Pivotal Trial Actually Show?

The approval rested on MSB-GVHD001 (NCT02336230), a multicenter, prospective, single-arm study in 54 children with SR-aGVHD after allogeneic transplant. Patients had Grade B to D disease. Grade B skin-only disease was excluded. Everyone had failed high-dose steroids, and nobody had already started a second-line systemic therapy for aGVHD before screening.

The peer-reviewed write-up is Kurtzberg and colleagues in Biology of Blood and Marrow Transplantation in 2020 (doi:10.1016/j.bbmt.2020.01.018). The FDA's own summary of the same study is the cleanest place to start for the approved numbers.

What the FDA reported

• Overall response at day 28: 70% (95% CI 56.4 to 82.0).
• Complete response: 30%.
• Partial response: 41%.
• Median duration of response: 54 days (range 7 to 159+), measured from the day-28 response until progression, a new systemic aGVHD therapy, or death from any cause.

What the published paper added

In the Kurtzberg paper, day-28 overall response was 70.4%, which beat a pre-specified historical control rate of 45%. Overall survival was 74.1% at day 100 and 68.5% at day 180. Day-28 responders lived longer than nonresponders through day 100 (86.8% vs 47.1%) and day 180 (78.9% vs 43.8%). The authors reported no identified infusion-related toxicities.

Those survival numbers matter for a disease that can kill children who do not respond. They still come from a single-arm study with no randomized placebo arm. Keep that in your pocket when someone tries to turn one approval into a blank check for every MSC clinic on Google.

What Are the Risks?

On the FDA label, the most common nonlaboratory adverse reactions (incidence 20% or higher) were viral infectious disorders, bacterial infectious disorders, infection with an unspecified pathogen, fever, hemorrhage, edema, abdominal pain, and hypertension.

Read that list again. These are children who already had a transplant and steroid-refractory GVHD. Infections are part of that world. The point is not "MSCs are dangerous." The point is that an approved cell drug still comes with a real safety profile, reviewed and listed in black and white.

What Is Happening With Ryoncil in 2025 and 2026?

Approvals do not freeze a product in place. Mesoblast has been pushing into adults and into other inflammatory diseases.

Adult steroid-refractory acute GVHD

In November 2025, Mesoblast announced a collaboration with the NIH-funded Blood and Marrow Transplant Clinical Trials Network on a pivotal adult trial (Mesoblast, November 20, 2025). Adults with severe SR-aGVHD still do poorly when steroids fail. Ruxolitinib is an approved second-line option, but a large share of Grade III/IV patients still do not respond by day 28.

The registered study is NCT07568535: a randomized, double-blind, placebo-controlled phase 3 trial of remestemcel-L plus ruxolitinib versus ruxolitinib plus placebo in adults with Grade III–IV SR-aGVHD. Estimated enrollment is 180. As of this writing the registry lists the trial as not yet recruiting, with a start date of August 31, 2026. Primary endpoint: overall response at day 28.

So for adults, Ryoncil is still investigational. That is the honest answer.

Duchenne muscular dystrophy

In April 2026, Mesoblast said the FDA cleared an IND so it can move straight into a registrational trial of Ryoncil in Duchenne muscular dystrophy (Mesoblast SEC exhibit, April 7, 2026). The planned trial randomizes 76 children ages 5 to 9 to Ryoncil (seven infusions of 2 × 10⁶ cells/kg over nine months) or placebo, on top of standard care. Primary endpoint: time-to-stand at nine months.

That is a different disease, a different bet, and not an approved use. Preclinical rationale and pediatric safety history are reasons a company gets to run the trial. They are not reasons a clinic gets to sell "Ryoncil for DMD" out the back door.

China Approved an Umbilical Cord MSC for GVHD Too

One more piece of context, because people will ask.

In early 2025, China's National Medical Products Administration conditionally approved Amimestrocel Injection (trade name Ruibosheng), a human umbilical cord-derived MSC product, for steroid-refractory acute GVHD with predominant gastrointestinal involvement in patients 14 and older (NMPA English notice).

Same disease family. Different country. Different cell source. Different product. Conditional approval is not the same as a full U.S. BLA. The useful takeaway is simpler: regulators in more than one country have now licensed specific MSC drugs for specific GVHD indications after reviewing specific data packages. That is progress. It is not a permission slip for every MSC vial everywhere.

Is Ryoncil the Same as Clinic MSC Therapy?

No.

Same broad cell family. Different source. Different manufacturing. Different legal status. Different indication.

Ryoncil is a named, lot-controlled biologic drug. Clinics that offer umbilical cord MSC IVs or injections are usually operating under a different framework. In the U.S., that often means HCT/P 361 "minimally manipulated" tissue rules, not a BLA. Those products are not FDA-approved to diagnose, treat, cure, or prevent any disease.

If a marketer says "MSCs are FDA-approved now" without naming Ryoncil, the indication, the age group, and the manufacturer, they are blurring categories on purpose. Ask them which product, which BLA, and which label. If they can't answer, walk.

Our guide to stem cell therapy and FDA approval walks through that distinction in plain English. So does our look at Japan's first iPS cell therapy approvals, which is another example of a real regulatory milestone that still does not travel to every clinic product.

Where The Stem Cell Club Fits

We offer umbilical cord Wharton's Jelly MSC options sourced from an FDA-registered U.S. lab. Registration covers facility and manufacturing standards. It is not FDA approval of the product.

We do not offer Ryoncil. We do not treat graft-versus-host disease. We do not claim our cells are remestemcel-L, and we do not borrow Ryoncil's pediatric GVHD data to sell joint, IV, or wellness services.

If you or your child has SR-aGVHD after a transplant, that conversation belongs with the transplant team and a center that can prescribe an approved product or enroll in a registered trial. Not with a cash-pay regenerative clinic.

If you are comparing MSC options for other reasons, ask about cell source, testing, viability documentation, and FDA status without the fog. Our science page explains how we source. Our review of 2026 knee osteoarthritis trials shows how mixed MSC evidence can look outside a single approved indication. And our page on stem cell therapy side effects is worth reading before any appointment.

Questions to Ask Anyone Selling "FDA-Approved Stem Cells"

• Which product, exactly? Brand name, generic name, manufacturer.
• Which indication is on the label? If they say "MSCs" without naming pediatric SR-aGVHD, press harder.
• Is this Ryoncil? If yes, ask why a regenerative clinic is dispensing an oncology/transplant biologic.
• If it is not Ryoncil, why say FDA-approved? Lab registration is not the same thing.
• What published study covers this exact product for my condition? Demand the DOI or the trial ID.

Frequently Asked Questions